#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=5 .
1-1	0-1	5	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Microparticles as an Indicator of Disease Activity
2-1	4-18	Microparticles	substance[2]	new[2]	coref	3-1[0_2]
2-2	19-21	as	substance[2]	new[2]	_	_
2-3	22-24	an	substance[2]	new[2]	_	_
2-4	25-34	Indicator	substance[2]	new[2]	_	_
2-5	35-37	of	substance[2]	new[2]	_	_
2-6	38-45	Disease	substance[2]|abstract|abstract[4]	new[2]|new|new[4]	coref|coref|coref|coref	4-12|4-12[14_4]|4-12|4-12[14_4]
2-7	46-54	Activity	substance[2]|abstract[4]	new[2]|new[4]	_	_

#Text=Microparticles have been attracting increasing attention as potential indicators of eukaryotic cell activation .
3-1	55-69	Microparticles	substance	giv	ana	4-1
3-2	70-74	have	_	_	_	_
3-3	75-79	been	_	_	_	_
3-4	80-90	attracting	_	_	_	_
3-5	91-101	increasing	_	_	_	_
3-6	102-111	attention	abstract	new	_	_
3-7	112-114	as	_	_	_	_
3-8	115-124	potential	_	_	_	_
3-9	125-135	indicators	_	_	_	_
3-10	136-138	of	_	_	_	_
3-11	139-149	eukaryotic	event[8]	new[8]	_	_
3-12	150-154	cell	place|event[8]	new|new[8]	_	_
3-13	155-165	activation	event[8]	new[8]	_	_
3-14	166-167	.	_	_	_	_

#Text=They could provide valuable information on inflammatory processes in progress , disease activity , and the response to treatment as well as prognosis as a disease assessment indicator .
4-1	168-172	They	substance	giv	_	_
4-2	173-178	could	_	_	_	_
4-3	179-186	provide	_	_	_	_
4-4	187-195	valuable	abstract[10]	new[10]	_	_
4-5	196-207	information	abstract[10]	new[10]	_	_
4-6	208-210	on	abstract[10]	new[10]	_	_
4-7	211-223	inflammatory	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-8	224-233	processes	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-9	234-236	in	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-10	237-245	progress	abstract[10]|abstract[11]|abstract	new[10]|new[11]|new	_	_
4-11	246-247	,	abstract[10]|abstract[11]	new[10]|new[11]	_	_
4-12	248-255	disease	abstract[10]|abstract[11]|abstract|abstract[14]	new[10]|new[11]|giv|giv[14]	coref|coref|coref|coref	4-26|5-17[25_14]|4-26|5-17[25_14]
4-13	256-264	activity	abstract[10]|abstract[11]|abstract[14]	new[10]|new[11]|giv[14]	_	_
4-14	265-266	,	_	_	_	_
4-15	267-270	and	_	_	_	_
4-16	271-274	the	abstract[15]	new[15]	_	_
4-17	275-283	response	abstract[15]	new[15]	_	_
4-18	284-286	to	abstract[15]	new[15]	_	_
4-19	287-296	treatment	abstract[15]|abstract	new[15]|new	coref	15-6[130_0]
4-20	297-299	as	_	_	_	_
4-21	300-304	well	_	_	_	_
4-22	305-307	as	_	_	_	_
4-23	308-317	prognosis	abstract[17]	new[17]	_	_
4-24	318-320	as	abstract[17]	new[17]	_	_
4-25	321-322	a	abstract[17]	new[17]	_	_
4-26	323-330	disease	abstract[17]|abstract	new[17]|giv	coref	7-28
4-27	331-341	assessment	abstract[17]|abstract	new[17]|new	_	_
4-28	342-351	indicator	abstract[17]	new[17]	_	_
4-29	352-353	.	_	_	_	_

#Text=Hsu et al. demonstrated that release of MPs from platelets activated with collagen decreased considerably after the activity of kinase BTK was inhibited .
5-1	354-357	Hsu	person	new	_	_
5-2	358-360	et	_	_	_	_
5-3	361-364	al.	_	_	_	_
5-4	365-377	demonstrated	_	_	_	_
5-5	378-382	that	event[21]	new[21]	coref	6-22[38_21]
5-6	383-390	release	event[21]	new[21]	_	_
5-7	391-393	of	event[21]	new[21]	_	_
5-8	394-397	MPs	event[21]|object	new[21]|new	coref	8-5
5-9	398-402	from	_	_	_	_
5-10	403-412	platelets	object	new	_	_
5-11	413-422	activated	_	_	_	_
5-12	423-427	with	_	_	_	_
5-13	428-436	collagen	organization	new	_	_
5-14	437-446	decreased	_	_	_	_
5-15	447-459	considerably	_	_	_	_
5-16	460-465	after	_	_	_	_
5-17	466-469	the	abstract[25]	giv[25]	coref	7-27[52_25]
5-18	470-478	activity	abstract[25]	giv[25]	_	_
5-19	479-481	of	abstract[25]	giv[25]	_	_
5-20	482-488	kinase	abstract[25]|abstract|object[27]	giv[25]|new|new[27]	coref|coref	6-9[0_27]|6-9[0_27]
5-21	489-492	BTK	abstract[25]|object[27]	giv[25]|new[27]	_	_
5-22	493-496	was	_	_	_	_
5-23	497-506	inhibited	_	_	_	_
5-24	507-508	.	_	_	_	_

#Text=Reduction of PMPs numbers in other studies with BTK inhibitor in platelet cultures was associated with a decrease in production and the release of inflammatory cytokines IL-6 and IL-8 .
6-1	509-518	Reduction	abstract[28]	new[28]	coref	17-24[0_28]
6-2	519-521	of	abstract[28]	new[28]	_	_
6-3	522-526	PMPs	abstract[28]|abstract|quantity[30]	new[28]|new|new[30]	coref|coref	17-11|17-11
6-4	527-534	numbers	abstract[28]|quantity[30]	new[28]|new[30]	_	_
6-5	535-537	in	abstract[28]|quantity[30]	new[28]|new[30]	_	_
6-6	538-543	other	abstract[28]|quantity[30]|event[31]	new[28]|new[30]|new[31]	coref	11-13[100_31]
6-7	544-551	studies	abstract[28]|quantity[30]|event[31]	new[28]|new[30]|new[31]	_	_
6-8	552-556	with	abstract[28]|quantity[30]|event[31]	new[28]|new[30]|new[31]	_	_
6-9	557-560	BTK	abstract[28]|quantity[30]|event[31]|object|object[33]	new[28]|new[30]|new[31]|giv|new[33]	_	_
6-10	561-570	inhibitor	abstract[28]|quantity[30]|event[31]|object[33]	new[28]|new[30]|new[31]|new[33]	_	_
6-11	571-573	in	abstract[28]|quantity[30]|event[31]|object[33]	new[28]|new[30]|new[31]|new[33]	_	_
6-12	574-582	platelet	abstract[28]|quantity[30]|event[31]|object[33]|place|object[35]	new[28]|new[30]|new[31]|new[33]|new|new[35]	coref|coref	7-8|7-8
6-13	583-591	cultures	abstract[28]|quantity[30]|event[31]|object[33]|object[35]	new[28]|new[30]|new[31]|new[33]|new[35]	_	_
6-14	592-595	was	_	_	_	_
6-15	596-606	associated	_	_	_	_
6-16	607-611	with	_	_	_	_
6-17	612-613	a	event[36]	new[36]	coref	17-31[170_36]
6-18	614-622	decrease	event[36]	new[36]	_	_
6-19	623-625	in	event[36]	new[36]	_	_
6-20	626-636	production	event[36]|abstract	new[36]|new	coref	16-56[158_0]
6-21	637-640	and	event[36]	new[36]	_	_
6-22	641-644	the	event[36]|event[38]	new[36]|giv[38]	coref	16-53[156_38]
6-23	645-652	release	event[36]|event[38]	new[36]|giv[38]	_	_
6-24	653-655	of	event[36]|event[38]	new[36]|giv[38]	_	_
6-25	656-668	inflammatory	event[36]|event[38]|abstract[39]|event[40]	new[36]|giv[38]|new[39]|new[40]	_	_
6-26	669-678	cytokines	event[36]|event[38]|abstract[39]|event[40]	new[36]|giv[38]|new[39]|new[40]	_	_
6-27	679-683	IL-6	event[36]|event[38]|event[40]	new[36]|giv[38]|new[40]	_	_
6-28	684-687	and	event[36]|event[38]	new[36]|giv[38]	_	_
6-29	688-692	IL-8	event[36]|event[38]|event	new[36]|giv[38]|new	_	_
6-30	693-694	.	_	_	_	_

#Text=A considerable increase in the number of platelet , monocyte , and lymphocyte-derived microparticles ( CD3 , CD19 ) has been observed in RA patients with high disease activity . Rodrigez-Cario et al. examined the amount of circulating microparticles and their origin in 114 RA patients .
7-1	695-696	A	abstract[42]	new[42]	_	_
7-2	697-709	considerable	abstract[42]	new[42]	_	_
7-3	710-718	increase	abstract[42]	new[42]	_	_
7-4	719-721	in	abstract[42]	new[42]	_	_
7-5	722-725	the	abstract[42]|quantity[43]	new[42]|new[43]	_	_
7-6	726-732	number	abstract[42]|quantity[43]	new[42]|new[43]	_	_
7-7	733-735	of	abstract[42]|quantity[43]	new[42]|new[43]	_	_
7-8	736-744	platelet	abstract[42]|quantity[43]|object	new[42]|new[43]|giv	coref	8-7
7-9	745-746	,	abstract[42]|quantity[43]	new[42]|new[43]	_	_
7-10	747-755	monocyte	abstract[42]|quantity[43]|substance	new[42]|new[43]|new	_	_
7-11	756-757	,	abstract[42]|quantity[43]	new[42]|new[43]	_	_
7-12	758-761	and	abstract[42]|quantity[43]	new[42]|new[43]	_	_
7-13	762-780	lymphocyte-derived	abstract[42]|quantity[43]|abstract[46]	new[42]|new[43]|new[46]	appos	7-16[0_46]
7-14	781-795	microparticles	abstract[42]|quantity[43]|abstract[46]	new[42]|new[43]|new[46]	_	_
7-15	796-797	(	_	_	_	_
7-16	798-801	CD3	abstract	giv	coref	7-39[55_0]
7-17	802-803	,	_	_	_	_
7-18	804-808	CD19	abstract	new	_	_
7-19	809-810	)	_	_	_	_
7-20	811-814	has	_	_	_	_
7-21	815-819	been	_	_	_	_
7-22	820-828	observed	_	_	_	_
7-23	829-831	in	_	_	_	_
7-24	832-834	RA	organization|person[50]	new|new[50]	ana|coref|ana|coref	7-41[0_50]|7-45|7-41[0_50]|7-45
7-25	835-843	patients	person[50]	new[50]	_	_
7-26	844-848	with	person[50]	new[50]	_	_
7-27	849-853	high	person[50]|abstract[52]	new[50]|giv[52]	coref	9-47[84_52]
7-28	854-861	disease	person[50]|abstract|abstract[52]	new[50]|giv|giv[52]	coref	9-36
7-29	862-870	activity	person[50]|abstract[52]	new[50]|giv[52]	_	_
7-30	871-872	.	_	_	_	_
7-31	873-887	Rodrigez-Cario	person	new	_	_
7-32	888-890	et	_	_	_	_
7-33	891-894	al.	_	_	_	_
7-34	895-903	examined	_	_	_	_
7-35	904-907	the	quantity[54]	new[54]	coref	9-27[75_54]
7-36	908-914	amount	quantity[54]	new[54]	_	_
7-37	915-917	of	_	_	_	_
7-38	918-929	circulating	_	_	_	_
7-39	930-944	microparticles	abstract[55]	giv[55]	_	_
7-40	945-948	and	abstract[55]	giv[55]	_	_
7-41	949-954	their	abstract[55]|person|abstract[57]	giv[55]|giv|new[57]	coref|coref	7-44[59_0]|7-44[59_0]
7-42	955-961	origin	abstract[55]|abstract[57]	giv[55]|new[57]	_	_
7-43	962-964	in	abstract[55]|abstract[57]	giv[55]|new[57]	_	_
7-44	965-968	114	abstract[55]|abstract[57]|person[59]	giv[55]|new[57]|giv[59]	coref	12-17[107_59]
7-45	969-971	RA	abstract[55]|abstract[57]|organization|person[59]	giv[55]|new[57]|giv|giv[59]	coref	9-14
7-46	972-980	patients	abstract[55]|abstract[57]|person[59]	giv[55]|new[57]|giv[59]	_	_
7-47	981-982	.	_	_	_	_

#Text=The total number of MPs in platelet poor plasma was much higher in individuals with arthritis compared to a group of healthy individuals .
8-1	983-986	The	quantity[60]	new[60]	_	_
8-2	987-992	total	quantity[60]	new[60]	_	_
8-3	993-999	number	quantity[60]	new[60]	_	_
8-4	1000-1002	of	quantity[60]	new[60]	_	_
8-5	1003-1006	MPs	quantity[60]|quantity	new[60]|giv	coref	9-5
8-6	1007-1009	in	quantity[60]	new[60]	_	_
8-7	1010-1018	platelet	quantity[60]|object|object[63]	new[60]|giv|new[63]	_	_
8-8	1019-1023	poor	quantity[60]|object[63]	new[60]|new[63]	_	_
8-9	1024-1030	plasma	quantity[60]|object[63]	new[60]|new[63]	_	_
8-10	1031-1034	was	_	_	_	_
8-11	1035-1039	much	_	_	_	_
8-12	1040-1046	higher	_	_	_	_
8-13	1047-1049	in	_	_	_	_
8-14	1050-1061	individuals	person[64]	new[64]	coref	8-19[66_64]
8-15	1062-1066	with	person[64]	new[64]	_	_
8-16	1067-1076	arthritis	person[64]|abstract	new[64]|new	coref	15-18[135_0]
8-17	1077-1085	compared	_	_	_	_
8-18	1086-1088	to	_	_	_	_
8-19	1089-1090	a	person[66]	giv[66]	_	_
8-20	1091-1096	group	person[66]	giv[66]	_	_
8-21	1097-1099	of	person[66]	giv[66]	_	_
8-22	1100-1107	healthy	person[66]	giv[66]	_	_
8-23	1108-1119	individuals	person[66]	giv[66]	_	_
8-24	1120-1121	.	_	_	_	_

#Text=The occurrence of different MPs subtypes in this study differed considerably in the RA group and was associated with the clinical course of joint inflammation : The amount of endothelial MPs was associated with the disease duration , the amount of granulocyte MPs was associated with the disease activity as assessed by DAS28 , whereas the amount of monocyte-derived MPs was associated with the presence of the rheumatoid factor .
9-1	1122-1125	The	abstract[67]	new[67]	_	_
9-2	1126-1136	occurrence	abstract[67]	new[67]	_	_
9-3	1137-1139	of	abstract[67]	new[67]	_	_
9-4	1140-1149	different	abstract[67]|abstract[69]	new[67]|new[69]	_	_
9-5	1150-1153	MPs	abstract[67]|object|abstract[69]	new[67]|giv|new[69]	coref	9-30[77_0]
9-6	1154-1162	subtypes	abstract[67]|abstract[69]	new[67]|new[69]	_	_
9-7	1163-1165	in	abstract[67]|abstract[69]	new[67]|new[69]	_	_
9-8	1166-1170	this	abstract[67]|abstract[69]|abstract[70]	new[67]|new[69]|new[70]	coref	12-14[106_70]
9-9	1171-1176	study	abstract[67]|abstract[69]|abstract[70]	new[67]|new[69]|new[70]	_	_
9-10	1177-1185	differed	_	_	_	_
9-11	1186-1198	considerably	_	_	_	_
9-12	1199-1201	in	_	_	_	_
9-13	1202-1205	the	abstract[72]	new[72]	_	_
9-14	1206-1208	RA	organization|abstract[72]	giv|new[72]	coref	11-20
9-15	1209-1214	group	abstract[72]	new[72]	_	_
9-16	1215-1218	and	_	_	_	_
9-17	1219-1222	was	_	_	_	_
9-18	1223-1233	associated	_	_	_	_
9-19	1234-1238	with	_	_	_	_
9-20	1239-1242	the	abstract[73]	new[73]	_	_
9-21	1243-1251	clinical	abstract[73]	new[73]	_	_
9-22	1252-1258	course	abstract[73]	new[73]	_	_
9-23	1259-1261	of	abstract[73]	new[73]	_	_
9-24	1262-1267	joint	abstract[73]|abstract[74]	new[73]|new[74]	coref	16-51[0_74]
9-25	1268-1280	inflammation	abstract[73]|abstract[74]	new[73]|new[74]	_	_
9-26	1281-1282	:	_	_	_	_
9-27	1283-1286	The	quantity[75]	giv[75]	_	_
9-28	1287-1293	amount	quantity[75]	giv[75]	_	_
9-29	1294-1296	of	quantity[75]	giv[75]	_	_
9-30	1297-1308	endothelial	quantity[75]|person|object[77]	giv[75]|new|giv[77]	coref|coref	9-42[82_77]|9-42[82_77]
9-31	1309-1312	MPs	quantity[75]|object[77]	giv[75]|giv[77]	_	_
9-32	1313-1316	was	_	_	_	_
9-33	1317-1327	associated	_	_	_	_
9-34	1328-1332	with	_	_	_	_
9-35	1333-1336	the	abstract[79]	new[79]	_	_
9-36	1337-1344	disease	abstract|abstract[79]	giv|new[79]	coref	9-48
9-37	1345-1353	duration	abstract[79]	new[79]	_	_
9-38	1354-1355	,	_	_	_	_
9-39	1356-1359	the	quantity[80]	new[80]	_	_
9-40	1360-1366	amount	quantity[80]	new[80]	_	_
9-41	1367-1369	of	quantity[80]	new[80]	_	_
9-42	1370-1381	granulocyte	quantity[80]|person|object[82]	new[80]|new|giv[82]	coref|coref	9-59[87_82]|9-59[87_82]
9-43	1382-1385	MPs	quantity[80]|object[82]	new[80]|giv[82]	_	_
9-44	1386-1389	was	_	_	_	_
9-45	1390-1400	associated	_	_	_	_
9-46	1401-1405	with	_	_	_	_
9-47	1406-1409	the	abstract[84]	giv[84]	coref	11-20[103_84]
9-48	1410-1417	disease	abstract|abstract[84]	giv|giv[84]	coref	13-2
9-49	1418-1426	activity	abstract[84]	giv[84]	_	_
9-50	1427-1429	as	_	_	_	_
9-51	1430-1438	assessed	_	_	_	_
9-52	1439-1441	by	_	_	_	_
9-53	1442-1447	DAS28	object	new	coref	13-19
9-54	1448-1449	,	_	_	_	_
9-55	1450-1457	whereas	_	_	_	_
9-56	1458-1461	the	quantity[86]	new[86]	_	_
9-57	1462-1468	amount	quantity[86]	new[86]	_	_
9-58	1469-1471	of	quantity[86]	new[86]	_	_
9-59	1472-1488	monocyte-derived	quantity[86]|object[87]	new[86]|giv[87]	coref	10-4[0_87]
9-60	1489-1492	MPs	quantity[86]|object[87]	new[86]|giv[87]	_	_
9-61	1493-1496	was	_	_	_	_
9-62	1497-1507	associated	_	_	_	_
9-63	1508-1512	with	_	_	_	_
9-64	1513-1516	the	abstract[88]	new[88]	_	_
9-65	1517-1525	presence	abstract[88]	new[88]	_	_
9-66	1526-1528	of	abstract[88]	new[88]	_	_
9-67	1529-1532	the	abstract[88]|abstract[90]	new[88]|new[90]	_	_
9-68	1533-1543	rheumatoid	abstract[88]|abstract|abstract[90]	new[88]|new|new[90]	coref	15-18
9-69	1544-1550	factor	abstract[88]|abstract[90]	new[88]|new[90]	_	_
9-70	1551-1552	.	_	_	_	_

#Text=The amount of MPs was also associated with the presence of traditional cardiovascular risk factors .
10-1	1553-1556	The	quantity[91]	new[91]	coref	14-12[123_91]
10-2	1557-1563	amount	quantity[91]	new[91]	_	_
10-3	1564-1566	of	quantity[91]	new[91]	_	_
10-4	1567-1570	MPs	quantity[91]|abstract	new[91]|giv	coref	14-16[124_0]
10-5	1571-1574	was	_	_	_	_
10-6	1575-1579	also	_	_	_	_
10-7	1580-1590	associated	_	_	_	_
10-8	1591-1595	with	_	_	_	_
10-9	1596-1599	the	abstract[93]	new[93]	_	_
10-10	1600-1608	presence	abstract[93]	new[93]	_	_
10-11	1609-1611	of	abstract[93]	new[93]	_	_
10-12	1612-1623	traditional	abstract[93]|abstract[96]	new[93]|new[96]	_	_
10-13	1624-1638	cardiovascular	abstract[93]|abstract|abstract[96]	new[93]|new|new[96]	_	_
10-14	1639-1643	risk	abstract[93]|abstract|abstract[96]	new[93]|new|new[96]	_	_
10-15	1644-1651	factors	abstract[93]|abstract[96]	new[93]|new[96]	_	_
10-16	1652-1653	.	_	_	_	_

#Text=The findings of Cloutier et al. could indicate the possibility of using the studies of circulating mpICs to assess RA activity .
11-1	1654-1657	The	abstract[97]	new[97]	_	_
11-2	1658-1666	findings	abstract[97]	new[97]	_	_
11-3	1667-1669	of	abstract[97]	new[97]	_	_
11-4	1670-1678	Cloutier	abstract[97]|person	new[97]|new	_	_
11-5	1679-1681	et	abstract[97]	new[97]	_	_
11-6	1682-1685	al.	abstract[97]	new[97]	_	_
11-7	1686-1691	could	_	_	_	_
11-8	1692-1700	indicate	_	_	_	_
11-9	1701-1704	the	abstract[99]	new[99]	_	_
11-10	1705-1716	possibility	abstract[99]	new[99]	_	_
11-11	1717-1719	of	_	_	_	_
11-12	1720-1725	using	_	_	_	_
11-13	1726-1729	the	event[100]	giv[100]	_	_
11-14	1730-1737	studies	event[100]	giv[100]	_	_
11-15	1738-1740	of	_	_	_	_
11-16	1741-1752	circulating	_	_	_	_
11-17	1753-1758	mpICs	abstract	new	_	_
11-18	1759-1761	to	_	_	_	_
11-19	1762-1768	assess	_	_	_	_
11-20	1769-1771	RA	organization|abstract[103]	giv|giv[103]	coref|coref|coref|coref	12-24|13-1[111_103]|12-24|13-1[111_103]
11-21	1772-1780	activity	abstract[103]	giv[103]	_	_
11-22	1781-1782	.	_	_	_	_

#Text=However , different conclusions were presented by van Eijk et al. based on a study with 24 patients with an early form of RA .
12-1	1783-1790	However	_	_	_	_
12-2	1791-1792	,	_	_	_	_
12-3	1793-1802	different	abstract[104]	new[104]	_	_
12-4	1803-1814	conclusions	abstract[104]	new[104]	_	_
12-5	1815-1819	were	_	_	_	_
12-6	1820-1829	presented	_	_	_	_
12-7	1830-1832	by	_	_	_	_
12-8	1833-1836	van	person[105]	new[105]	_	_
12-9	1837-1841	Eijk	person[105]	new[105]	_	_
12-10	1842-1844	et	_	_	_	_
12-11	1845-1848	al.	_	_	_	_
12-12	1849-1854	based	_	_	_	_
12-13	1855-1857	on	_	_	_	_
12-14	1858-1859	a	abstract[106]	giv[106]	_	_
12-15	1860-1865	study	abstract[106]	giv[106]	_	_
12-16	1866-1870	with	abstract[106]	giv[106]	_	_
12-17	1871-1873	24	abstract[106]|person[107]	giv[106]|giv[107]	coref	14-27[128_107]
12-18	1874-1882	patients	abstract[106]|person[107]	giv[106]|giv[107]	_	_
12-19	1883-1887	with	abstract[106]|person[107]	giv[106]|giv[107]	_	_
12-20	1888-1890	an	abstract[106]|person[107]|abstract[108]	giv[106]|giv[107]|new[108]	_	_
12-21	1891-1896	early	abstract[106]|person[107]|abstract[108]	giv[106]|giv[107]|new[108]	_	_
12-22	1897-1901	form	abstract[106]|person[107]|abstract[108]	giv[106]|giv[107]|new[108]	_	_
12-23	1902-1904	of	abstract[106]|person[107]|abstract[108]	giv[106]|giv[107]|new[108]	_	_
12-24	1905-1907	RA	abstract[106]|person[107]|abstract[108]|abstract	giv[106]|giv[107]|new[108]|giv	_	_
12-25	1908-1909	.	_	_	_	_

#Text=The disease activity was assessed based on the ESR , C-reactive protein ( CRP ) level , and DAS28 score .
13-1	1910-1913	The	abstract[111]	giv[111]	_	_
13-2	1914-1921	disease	abstract|abstract[111]	giv|giv[111]	coref	17-36
13-3	1922-1930	activity	abstract[111]	giv[111]	_	_
13-4	1931-1934	was	_	_	_	_
13-5	1935-1943	assessed	_	_	_	_
13-6	1944-1949	based	_	_	_	_
13-7	1950-1952	on	_	_	_	_
13-8	1953-1956	the	abstract[112]	new[112]	coref	16-4[0_112]
13-9	1957-1960	ESR	abstract[112]	new[112]	_	_
13-10	1961-1962	,	_	_	_	_
13-11	1963-1973	C-reactive	object|abstract[114]	new|new[114]	appos|appos	13-14[0_114]|13-14[0_114]
13-12	1974-1981	protein	abstract[114]	new[114]	_	_
13-13	1982-1983	(	_	_	_	_
13-14	1984-1987	CRP	abstract	giv	coref	16-6
13-15	1988-1989	)	_	_	_	_
13-16	1990-1995	level	quantity	new	coref	14-3[119_0]
13-17	1996-1997	,	_	_	_	_
13-18	1998-2001	and	_	_	_	_
13-19	2002-2007	DAS28	abstract|abstract[118]	giv|new[118]	coref|coref	16-9|16-9
13-20	2008-2013	score	abstract[118]	new[118]	_	_
13-21	2014-2015	.	_	_	_	_

#Text=Moreover , the level of serum amyloid-P ( SAP ) and the amount of circulating MPs and MPs presenting the C1q complement component was determined in the patients .
14-1	2016-2024	Moreover	_	_	_	_
14-2	2025-2026	,	_	_	_	_
14-3	2027-2030	the	quantity[119]	giv[119]	_	_
14-4	2031-2036	level	quantity[119]	giv[119]	_	_
14-5	2037-2039	of	quantity[119]	giv[119]	_	_
14-6	2040-2045	serum	quantity[119]|abstract|abstract[121]	giv[119]|new|new[121]	_	_
14-7	2046-2055	amyloid-P	quantity[119]|abstract[121]	giv[119]|new[121]	_	_
14-8	2056-2057	(	_	_	_	_
14-9	2058-2061	SAP	substance	new	_	_
14-10	2062-2063	)	_	_	_	_
14-11	2064-2067	and	_	_	_	_
14-12	2068-2071	the	quantity[123]	giv[123]	coref	16-24[146_123]
14-13	2072-2078	amount	quantity[123]	giv[123]	_	_
14-14	2079-2081	of	_	_	_	_
14-15	2082-2093	circulating	_	_	_	_
14-16	2094-2097	MPs	quantity[124]	giv[124]	coref	16-29[0_124]
14-17	2098-2101	and	quantity[124]	giv[124]	_	_
14-18	2102-2105	MPs	quantity[124]	giv[124]	_	_
14-19	2106-2116	presenting	_	_	_	_
14-20	2117-2120	the	abstract[127]	new[127]	coref	16-34[150_127]
14-21	2121-2124	C1q	abstract|abstract[127]	new|new[127]	coref	16-36
14-22	2125-2135	complement	object|abstract[127]	new|new[127]	_	_
14-23	2136-2145	component	abstract[127]	new[127]	_	_
14-24	2146-2149	was	_	_	_	_
14-25	2150-2160	determined	_	_	_	_
14-26	2161-2163	in	_	_	_	_
14-27	2164-2167	the	person[128]	giv[128]	coref	15-1[129_128]
14-28	2168-2176	patients	person[128]	giv[128]	_	_
14-29	2177-2178	.	_	_	_	_

#Text=Nine patients were reassessed after an eight-week intensive treatment according to the COBRA ( COmBination therapy in Rheumatoid Arthritis ) regimen , which included a combined treatment with methotrexate , sulfasalazine , and prednisolone .
15-1	2179-2183	Nine	person[129]	giv[129]	_	_
15-2	2184-2192	patients	person[129]	giv[129]	_	_
15-3	2193-2197	were	_	_	_	_
15-4	2198-2208	reassessed	_	_	_	_
15-5	2209-2214	after	_	_	_	_
15-6	2215-2217	an	abstract[130]	giv[130]	coref	15-25[137_130]
15-7	2218-2228	eight-week	abstract[130]	giv[130]	_	_
15-8	2229-2238	intensive	abstract[130]	giv[130]	_	_
15-9	2239-2248	treatment	abstract[130]	giv[130]	_	_
15-10	2249-2258	according	abstract[130]	giv[130]	_	_
15-11	2259-2261	to	abstract[130]	giv[130]	_	_
15-12	2262-2265	the	abstract[130]|abstract[131]	giv[130]|new[131]	appos	15-14[133_131]
15-13	2266-2271	COBRA	abstract[130]|abstract[131]	giv[130]|new[131]	_	_
15-14	2272-2273	(	abstract[133]	giv[133]	_	_
15-15	2274-2285	COmBination	abstract|abstract[133]	new|giv[133]	_	_
15-16	2286-2293	therapy	abstract[133]	giv[133]	_	_
15-17	2294-2296	in	abstract[133]	giv[133]	_	_
15-18	2297-2307	Rheumatoid	abstract[133]|object|abstract[135]	giv[133]|giv|giv[135]	coref|coref	17-21[0_135]|17-21[0_135]
15-19	2308-2317	Arthritis	abstract[133]|abstract[135]	giv[133]|giv[135]	_	_
15-20	2318-2319	)	abstract[133]	giv[133]	_	_
15-21	2320-2327	regimen	abstract[133]|abstract	giv[133]|new	_	_
15-22	2328-2329	,	_	_	_	_
15-23	2330-2335	which	_	_	_	_
15-24	2336-2344	included	_	_	_	_
15-25	2345-2346	a	abstract[137]	giv[137]	coref	16-15[144_137]
15-26	2347-2355	combined	abstract[137]	giv[137]	_	_
15-27	2356-2365	treatment	abstract[137]	giv[137]	_	_
15-28	2366-2370	with	abstract[137]	giv[137]	_	_
15-29	2371-2383	methotrexate	abstract[137]|substance	giv[137]|new	_	_
15-30	2384-2385	,	abstract[137]	giv[137]	_	_
15-31	2386-2399	sulfasalazine	abstract[137]|substance	giv[137]|new	_	_
15-32	2400-2401	,	abstract[137]	giv[137]	_	_
15-33	2402-2405	and	abstract[137]	giv[137]	_	_
15-34	2406-2418	prednisolone	abstract[137]|substance	giv[137]|new	_	_
15-35	2419-2420	.	_	_	_	_

#Text=As expected , ESR , CRP , and DAS28 improved as a result of the treatment ; however , contrary to expectations , neither the amount of circulating MPs , nor MPs with the attached C1q component decreased , which suggests the absence of any connection between the activity of inflammation and MPs release and mpIC production .
16-1	2421-2423	As	_	_	_	_
16-2	2424-2432	expected	_	_	_	_
16-3	2433-2434	,	_	_	_	_
16-4	2435-2438	ESR	abstract	giv	_	_
16-5	2439-2440	,	_	_	_	_
16-6	2441-2444	CRP	object	giv	_	_
16-7	2445-2446	,	_	_	_	_
16-8	2447-2450	and	_	_	_	_
16-9	2451-2456	DAS28	abstract	giv	_	_
16-10	2457-2465	improved	_	_	_	_
16-11	2466-2468	as	_	_	_	_
16-12	2469-2470	a	_	_	_	_
16-13	2471-2477	result	_	_	_	_
16-14	2478-2480	of	_	_	_	_
16-15	2481-2484	the	abstract[144]	giv[144]	_	_
16-16	2485-2494	treatment	abstract[144]	giv[144]	_	_
16-17	2495-2496	;	_	_	_	_
16-18	2497-2504	however	_	_	_	_
16-19	2505-2506	,	_	_	_	_
16-20	2507-2515	contrary	_	_	_	_
16-21	2516-2518	to	_	_	_	_
16-22	2519-2531	expectations	abstract	new	_	_
16-23	2532-2533	,	_	_	_	_
16-24	2534-2541	neither	quantity[146]	giv[146]	_	_
16-25	2542-2545	the	quantity[146]	giv[146]	_	_
16-26	2546-2552	amount	quantity[146]	giv[146]	_	_
16-27	2553-2555	of	_	_	_	_
16-28	2556-2567	circulating	_	_	_	_
16-29	2568-2571	MPs	object	giv	coref	16-32[148_0]
16-30	2572-2573	,	_	_	_	_
16-31	2574-2577	nor	_	_	_	_
16-32	2578-2581	MPs	object[148]	giv[148]	coref	16-53[0_148]
16-33	2582-2586	with	object[148]	giv[148]	_	_
16-34	2587-2590	the	object[148]|abstract[150]	giv[148]|giv[150]	_	_
16-35	2591-2599	attached	object[148]|abstract[150]	giv[148]|giv[150]	_	_
16-36	2600-2603	C1q	object[148]|abstract|abstract[150]	giv[148]|giv|giv[150]	_	_
16-37	2604-2613	component	object[148]|abstract[150]	giv[148]|giv[150]	_	_
16-38	2614-2623	decreased	_	_	_	_
16-39	2624-2625	,	_	_	_	_
16-40	2626-2631	which	_	_	_	_
16-41	2632-2640	suggests	_	_	_	_
16-42	2641-2644	the	abstract[151]	new[151]	_	_
16-43	2645-2652	absence	abstract[151]	new[151]	_	_
16-44	2653-2655	of	abstract[151]	new[151]	_	_
16-45	2656-2659	any	abstract[151]|abstract[152]	new[151]|new[152]	_	_
16-46	2660-2670	connection	abstract[151]|abstract[152]	new[151]|new[152]	_	_
16-47	2671-2678	between	abstract[151]|abstract[152]	new[151]|new[152]	_	_
16-48	2679-2682	the	abstract[151]|abstract[152]|abstract[153]	new[151]|new[152]|new[153]	coref	17-35[172_153]
16-49	2683-2691	activity	abstract[151]|abstract[152]|abstract[153]	new[151]|new[152]|new[153]	_	_
16-50	2692-2694	of	abstract[151]|abstract[152]|abstract[153]	new[151]|new[152]|new[153]	_	_
16-51	2695-2707	inflammation	abstract[151]|abstract[152]|abstract[153]|abstract	new[151]|new[152]|new[153]|giv	_	_
16-52	2708-2711	and	abstract[151]|abstract[152]|abstract[153]	new[151]|new[152]|new[153]	_	_
16-53	2712-2715	MPs	abstract[151]|abstract[152]|abstract[153]|substance|event[156]	new[151]|new[152]|new[153]|giv|giv[156]	_	_
16-54	2716-2723	release	abstract[151]|abstract[152]|abstract[153]|event[156]	new[151]|new[152]|new[153]|giv[156]	_	_
16-55	2724-2727	and	abstract[151]|abstract[152]|abstract[153]	new[151]|new[152]|new[153]	_	_
16-56	2728-2732	mpIC	abstract[151]|abstract[152]|abstract[153]|object|abstract[158]	new[151]|new[152]|new[153]|new|giv[158]	_	_
16-57	2733-2743	production	abstract[151]|abstract[152]|abstract[153]|abstract[158]	new[151]|new[152]|new[153]|giv[158]	_	_
16-58	2744-2745	.	_	_	_	_

#Text=In a recent paper , Chen demonstrated that inhibition of PMPs formation in an animal model of CIA ( collagen-induced arthritis ) and reduction of circulating PMPs was associated with a clinical decrease in the disease activity assessed as joint swelling and stiffness .
17-1	2746-2748	In	_	_	_	_
17-2	2749-2750	a	abstract[159]	new[159]	_	_
17-3	2751-2757	recent	abstract[159]	new[159]	_	_
17-4	2758-2763	paper	abstract[159]	new[159]	_	_
17-5	2764-2765	,	_	_	_	_
17-6	2766-2770	Chen	person	new	_	_
17-7	2771-2783	demonstrated	_	_	_	_
17-8	2784-2788	that	abstract[161]	new[161]	_	_
17-9	2789-2799	inhibition	abstract[161]	new[161]	_	_
17-10	2800-2802	of	abstract[161]	new[161]	_	_
17-11	2803-2807	PMPs	abstract[161]|object|abstract[163]	new[161]|giv|new[163]	coref|coref	17-27|17-27
17-12	2808-2817	formation	abstract[161]|abstract[163]	new[161]|new[163]	_	_
17-13	2818-2820	in	abstract[161]|abstract[163]	new[161]|new[163]	_	_
17-14	2821-2823	an	abstract[161]|abstract[163]|abstract[165]	new[161]|new[163]|new[165]	_	_
17-15	2824-2830	animal	abstract[161]|abstract[163]|person|abstract[165]	new[161]|new[163]|new|new[165]	_	_
17-16	2831-2836	model	abstract[161]|abstract[163]|abstract[165]	new[161]|new[163]|new[165]	_	_
17-17	2837-2839	of	abstract[161]|abstract[163]|abstract[165]	new[161]|new[163]|new[165]	_	_
17-18	2840-2843	CIA	abstract[161]|abstract[163]|abstract[165]|organization	new[161]|new[163]|new[165]|new	_	_
17-19	2844-2845	(	_	_	_	_
17-20	2846-2862	collagen-induced	_	_	_	_
17-21	2863-2872	arthritis	abstract	giv	_	_
17-22	2873-2874	)	_	_	_	_
17-23	2875-2878	and	_	_	_	_
17-24	2879-2888	reduction	abstract	giv	_	_
17-25	2889-2891	of	_	_	_	_
17-26	2892-2903	circulating	_	_	_	_
17-27	2904-2908	PMPs	object	giv	_	_
17-28	2909-2912	was	_	_	_	_
17-29	2913-2923	associated	_	_	_	_
17-30	2924-2928	with	_	_	_	_
17-31	2929-2930	a	event[170]	giv[170]	_	_
17-32	2931-2939	clinical	event[170]	giv[170]	_	_
17-33	2940-2948	decrease	event[170]	giv[170]	_	_
17-34	2949-2951	in	event[170]	giv[170]	_	_
17-35	2952-2955	the	event[170]|abstract[172]	giv[170]|giv[172]	_	_
17-36	2956-2963	disease	event[170]|abstract|abstract[172]	giv[170]|giv|giv[172]	_	_
17-37	2964-2972	activity	event[170]|abstract[172]	giv[170]|giv[172]	_	_
17-38	2973-2981	assessed	_	_	_	_
17-39	2982-2984	as	_	_	_	_
17-40	2985-2990	joint	_	_	_	_
17-41	2991-2999	swelling	_	_	_	_
17-42	3000-3003	and	_	_	_	_
17-43	3004-3013	stiffness	_	_	_	_
17-44	3014-3015	.	_	_	_	_
